Discovery and optimization of 2-(4-substituted-pyrrolo[2,3-b]pyridin-3-yl)methylene-4-hydroxybenzofuran-3(2H)-ones as potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR).
Tsou, H.R., MacEwan, G., Birnberg, G., Grosu, G., Bursavich, M.G., Bard, J., Brooijmans, N., Toral-Barza, L., Hollander, I., Mansour, T.S., Ayral-Kaloustian, S., Yu, K.(2010) Bioorg Med Chem Lett 20: 2321-2325
- PubMed: 20188552 
- DOI: https://doi.org/10.1016/j.bmcl.2010.01.135
- Primary Citation of Related Structures:  
3LJ3 - PubMed Abstract: 
We discovered 2-(4-substituted-pyrrolo[2,3-b]pyridin-3-yl)methylene-4-hydroxybenzofuran-3(2H)-ones as potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR). Since phenolic OH groups pose metabolic liability, one of the two hydroxyl groups was selectively removed. The SAR data showed the structural features necessary for subnanomolar inhibitory activity against mTOR kinase as well as selectivity over PI3Kalpha. An X-ray co-crystal structure of one inhibitor with the mTOR-related PI3Kgamma revealed the key hydrogen bonding interactions.
Organizational Affiliation: 
Chemical Sciences, Wyeth Research, 401 N. Middletown Road, Pearl River, NY 10965, United States. tsouh@wyeth.com